EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

NCT03516214 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Bronchial Neoplasms

Interventions

DRUG: EGF816
DRUG: Trametinib

Sponsor

University of Cologne